Aging Medicine最新文献

{"title":"Factors Associated With Frailty Clinic Utilization by High-Need High-Risk Older Adult Veterans","authors":"Marianne Desir,&nbsp;Fei Tang,&nbsp;Carlos Gomez-Orozco,&nbsp;Stuti Dang","doi":"10.1002/agm2.70032","DOIUrl":"https://doi.org/10.1002/agm2.70032","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Clinical models incorporating multidomain assessment and interventions may be helpful for older adults with frailty and other higher-risk geriatric patients. Patient participation in these clinical programs is variable, however, and there is a need for greater understanding of the factors that influence participation. We aimed to identify patient characteristics associated with participation in an outpatient frailty clinic intervention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective study of high-need high-risk older adult patients who were offered a frailty clinic intervention designed to assess and address their medical, functional, psychological, and social needs (FIT clinic). Consistent with the Andersen Behavioral Model of Healthcare Utilization, we identified variables in the “predisposing,” “need,” and “enabling” domains that might relate to patient participation in the clinic. Bivariate analyses were employed to explore the potential roles of the identified variables in the observed levels of patient participation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the analyses of “predisposing” factors, being married and being of African American race were positively associated with FIT clinic participation (<i>p</i> = 0.021 and 0.036, respectively). With controlling for chronic conditions, however, African American race was no longer associated with clinic participation. In the analyses of “need” factors, patients with essential hypertension, type II diabetes mellitus, and/or overweight/obesity were more likely to attend the frailty clinic (<i>p</i> = 0.002, 0.012, and 0.013, respectively). There was less availability of data regarding potential “enabling” factors, and no statistically significant differences were found in the “enabling” domain.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The application of the Andersen Behavioral Model can provide insights into the participation patterns of high-risk older Veterans in clinical interventions involving comprehensive geriatric assessments and multidomain interventions, including frailty clinics.</p>\u0000 </section>\u0000 </div>","PeriodicalId":32862,"journal":{"name":"Aging Medicine","volume":"8 3","pages":"210-220"},"PeriodicalIF":2.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/agm2.70032","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144551332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Potentially Inappropriate Medication Use on Elderly Patients in a General Medicine Ward Using 2023 AGS Beers Criteria","authors":"Subash Karki,&nbsp;Rahi Bikram Thapa,&nbsp;Rajeev Shrestha","doi":"10.1002/agm2.70025","DOIUrl":"https://doi.org/10.1002/agm2.70025","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Potentially inappropriate medication (PIM) use is a significant concern among the elderly, a vulnerable population, due to physiological changes, and the risk of multiple comorbidities and polypharmacy. This study aimed to assess the use of PIM among elderly inpatients in tertiary care hospital in eastern Nepal.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A three-month prospective observational study was conducted, involving 200 eligible elderly patients admitted to general medicine ward. Relevant data were collected from patient case sheets, nursing and doctor cardex, discharge summaries, and via patient interviews. PIMs were identified based on the latest 2023 AGS Beers Criteria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 200 eligible patients, 108 (54.0%) were prescribed at least one PIM. Medications that should be avoided in older patients accounted for 32.2%, where prazosin and hyoscine were the most common. Additionally, 52.8% of the medications required cautious use, with diuretics being the most frequent one. Multivariate analysis revealed that patients with chronic kidney disease (CKD) and the number of prescribed medicines significantly influenced the likelihood of PIMs with an adjusted odd ratio of 6.730 (2.111–21.456) and 2.764 (1.448–5.276), respectively, at <i>p</i> &lt; 0.05.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>PIMs are more common among the elderly, with CKD and polypharmacy contributing significantly to their prevalence. To reduce PIM use, healthcare professionals, including clinical pharmacists, should implement targeted interventions, particularly for older adults with CKD who are managing with multiple medications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":32862,"journal":{"name":"Aging Medicine","volume":"8 3","pages":"238-248"},"PeriodicalIF":2.2,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/agm2.70025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144551315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phase 3 Multicenter, Double-Blind Study Comparing Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Alkem's Biosimilar Teriparatide Versus Reference Teriparatide in Postmenopausal Osteoporosis","authors":"Nitin Kapoor,&nbsp;Thomas Paul,&nbsp;Rajeshwar Nath Srivastava,&nbsp;Saurabh Singh,&nbsp;Sunil Maheshwari,&nbsp;Vishal Patil,&nbsp;Awadhesh Kumar Yadav,&nbsp;Girish Bhatia,&nbsp;Sushil H. Mankar,&nbsp;Joe Joseph Cherian,&nbsp;Surabhi Maheshwari,&nbsp;Sudeepti Srivastava,&nbsp;Dattatray Pawar,&nbsp;Roshan Pawar,&nbsp;Amol Aiwale,&nbsp;Amitrajit Pal,&nbsp;Yogesh Rane,&nbsp;Vinayaka Shahavi,&nbsp;Akhilesh Sharma","doi":"10.1002/agm2.70029","DOIUrl":"https://doi.org/10.1002/agm2.70029","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The primary purpose of this study was to compare the efficacy and safety of proposed biosimilar teriparatide with reference teriparatide in patients of postmenopausal osteoporosis. The secondary objectives were to assess the pharmacodynamic response of study drugs in postmenopausal osteoporosis and to assess the pharmacokinetic profile of biosimilar and reference teriparatide in a subset of subjects (a total of 30 evaluable subjects i.e., 15 subjects in reference arm and 15 subjects in biosimilar arm).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A prospective, active-controlled, randomized, double-blind, phase III study included postmenopausal women (50–80 years of age) with at least 5 years since menopause diagnosed with osteoporosis (&lt;i&gt;T-SCORE&lt;/i&gt; ≤ −2.5 SD at lumbar spine or femoral neck) randomized 2:1 to receive either Alkem's biosimilar teriparatide or reference teriparatide 20 μg once daily subcutaneously for 48 weeks. All subjects received calcium 1000 mg and vitamin D3 500 IU once daily orally. The primary efficacy endpoint was percent change in bone mineral density (BMD) at lumbar spine and femoral neck from baseline to 48 weeks. Safety outcomes, pharmacokinetics, and immunogenicity were also evaluated. Secondary endpoints included change from baseline in pharmacodynamic parameters like serum P1NP, which were analyzed at randomization, at week 12, 24, and 48.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In total, 177 patients (114 in biosimilar group and 63 in reference group) were randomized. The percent change from baseline to 48 weeks in lumbar spine BMD (least square mean [LSM] ± standard error [SE]) was 8.58% ± 0.85 in the biosimilar group and 8.02% ± 1.23 in the reference group. The estimated between-group difference (95% confidence interval [CI]) was −0.56% (−2.43% to 3.54%) within the prespecified noninferiority margin (− 2.43%), which indicates noninferiority of biosimilar teriparatide compared to reference teriparatide. The percent change in femoral neck BMD from baseline to 48 weeks (LSM ± SE) was 3.94% ± 0.83 in the biosimilar group and 2.50% ± 1.20 in the reference group. The estimated between-group difference (95% CI) was 1.44% (−1.44% to 4.32%) within the prespecified noninferiority margin (−1.44%) indicating noninferiority of biosimilar teriparatide compared to reference teriparatide. Changes in P1NP (serum procollagen type 1 N terminal pro-peptide) were also similar between the groups. Safety profiles, including immunogenicity, were comparable.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 ","PeriodicalId":32862,"journal":{"name":"Aging Medicine","volume":"8 3","pages":"267-274"},"PeriodicalIF":2.2,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/agm2.70029","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144551303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Bazi Bushen Capsule on D-Galactose-Induced Human Endothelial Cell Senescence Through PI3K/Akt/eNOS Signaling Pathway","authors":"Lulu Yao,&nbsp;Fuyao Li,&nbsp;Jingnian Ni,&nbsp;Mingqing Wei,&nbsp;Ting Li,&nbsp;Jing Shi,&nbsp;Jinzhou Tian","doi":"10.1002/agm2.70031","DOIUrl":"https://doi.org/10.1002/agm2.70031","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>BaZi BuShen capsule (BZBS) is a Chinese herbal prescription with the function of nourishing the kidney, replenishing essence, and combating aging. This study aims to investigate the effects of BZBS on aging endothelial cells and to elucidate the underlying mechanisms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>An aging human brain microvascular endothelial cells (HBMECs) model was established using D-galactose (D-gal) for 24 h. The efficacy of the model was evaluated by the positive rate of senescence-associated β-galactosidase (SA-β-Gal) staining. The treatment was administered using drug-containing serum of BZBS. The experimental groups comprised the following: Control, Model, and groups treated with drug-containing serum at low (BZBSL), medium (BZBSM), and high (BZBSH) doses of BZBS, in addition to a pathway inhibitor group (LY294002 [5 μM/L]). Western blotting and immunofluorescence assays were conducted to evaluate the expression levels of proteins. Nitric oxide (NO) levels in the cells were detected using an Assay Kit. The experiments were independently repeated five times.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>D-gal significantly elevated the SA-β-Gal positive rate in HBMECs. Intervention with BZBS significantly reduced the percentage of SA-β-Gal positive cells (<i>p</i> &lt; 0.001). Compared to the Model group, drug-containing serum of BZBS significantly increased the expression levels of PI3K, p-Akt, Akt, and eNOS (<i>p</i> &lt; 0.010) and elevated NO levels in the cells (<i>p</i> &lt; 0.010), by which BZBS ameliorated HBMECs aging and enhanced the function of aging HBMECs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our findings indicate that BZBS can mitigate D-gal-induced aging in HBMECs by activating the PI3K/Akt/eNOS signaling pathway.</p>\u0000 </section>\u0000 </div>","PeriodicalId":32862,"journal":{"name":"Aging Medicine","volume":"8 3","pages":"258-266"},"PeriodicalIF":2.2,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/agm2.70031","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144551231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetically Predicted 1400 Blood Metabolites in Relation to Risk of Prostate Cancer: A Mendelian Randomization Study","authors":"Xiaojin Lu,&nbsp;Yongming Chen,&nbsp;Yuxiao Jiang,&nbsp;Jiaxin Ning,&nbsp;Shengjie Liu,&nbsp;Zhengtong Lv,&nbsp;Miao Wang,&nbsp;Huiming Hou,&nbsp;Ming Liu","doi":"10.1002/agm2.70016","DOIUrl":"https://doi.org/10.1002/agm2.70016","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Metabolic dysregulation is common in cancer, yet evidence linking circulating metabolites to causal relationships in prostate cancer (PCa) is lacking. We performed a Mendelian randomization analysis utilizing 1400 blood metabolites to evaluate their roles in PCa.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Exposure data from genome-wide association studies (GWAS) was extracted from metabolite level GWAS involving 462,933 individuals of European descent. GWAS data for PCa were obtained from the UK Biobank (UKB) database (79,148 cases, 61,106 controls) for a two-sample Mendelian randomization (MR) preliminary analysis, where we investigated potential causal relationships between 1400 metabolites and PCa. Inverse variance weighting (IVW) was the primary method for causal analysis, with MR-Egger and weighted median as supplementary analyses to enhance robustness. Sensitivity analyses including Cochran <i>Q</i> test, MR-Egger intercept test, MR-PRESSO, and leave-one-out analysis were employed to evaluate the robustness of MR results. For significant associations, an additional independent PCa dataset was utilized for validation analysis and meta-analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our findings revealed significant associations between two metabolites and prostate cancer: Cysteinylglycine disulfide levels (OR: 0.999, 95% CI: 0.998–0.999, <i>p</i> = 0.004). Validation analyses showed a similar trend, and sensitivity analyses supported the robustness of MR estimates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our results suggest that Cysteinylglycine disulfide levels may have a causal relationship with increased PCa risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":32862,"journal":{"name":"Aging Medicine","volume":"8 3","pages":"249-257"},"PeriodicalIF":2.2,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/agm2.70016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144551304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese Expert Consensus on Standardized Outpatient Management of Sarcopenia in the Elderly (2024)","authors":"Zhang Qin,&nbsp;Kang Lin,&nbsp;Wang Jianye,&nbsp;Xi Huan,&nbsp;Yu Pulin,&nbsp;Zhang Cuntai,&nbsp;Hidenori Arai,&nbsp;Tuo Xiping,&nbsp;Yang Yunmei,&nbsp;Liu Xiaohong","doi":"10.1002/agm2.70010","DOIUrl":"https://doi.org/10.1002/agm2.70010","url":null,"abstract":"<p>Sarcopenia is an age-related disorder that influences the daily living ability of older adults and interacts with various chronic diseases. Older adults with sarcopenia typically experience a deterioration in their quality of life and healthy lifespan. The number of Chinese persons with sarcopenia is considerable, and the burden of sarcopenia is substantial; however, the specific sarcopenia clinics available for outpatients are insufficient. The promotion of sarcopenia clinics is beneficial for the early identification, standardized diagnosis, and treatment of older adults with sarcopenia, thereby helping to enhance their physical function and quality of life. This consensus incorporates the professional recommendations of Chinese geriatrics experts, synthesizes existing Chinese experiences in establishing sarcopenia clinics, offers guidance for managing sarcopenia clinics, and advocates for early identification, diagnosis, and intervention of sarcopenia in older adults.</p>","PeriodicalId":32862,"journal":{"name":"Aging Medicine","volume":"8 3","pages":"183-191"},"PeriodicalIF":2.2,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/agm2.70010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144551347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical Intervention and Prognosis of Intraductal Papillary Mucinous Adenoma in Elderly Patients: A Single Center Retrospective Study","authors":"Tianhan Sun,&nbsp;Meilan Liu,&nbsp;Qing Wang,&nbsp;Boyue Jiang,&nbsp;Tong Li,&nbsp;Jianfu Cao,&nbsp;Jinghai Song,&nbsp;Jingyong Xu,&nbsp;Hongyuan Cui","doi":"10.1002/agm2.70022","DOIUrl":"https://doi.org/10.1002/agm2.70022","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The incidence of intraductal papillary mucinous neoplasm (IPMN) is rising among elderly patients. This study aims to investigate the clinical features of IPMN in elderly patients (≥ 60 years), analyze risk factors for high-grade dysplasia (HGD) and invasive cancer (IC), and provide treatment recommendations for elderly patients with IPMN.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this single-center retrospective case–control study, 58 consecutive elderly patients (≥ 60 years) who underwent IPMN surgery at Beijing Hospital between January 2014 and November 2023 were included. Clinical characteristics across IPMN subtypes were compared, risk factors were analyzed, and the predictive values of the 2017 Fukuoka and 2023 Kyoto guidelines were evaluated. Follow-up and survival outcomes were also examined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The proportion of patients with main-duct IPMN (MD-IPMN) and mixed-type IPMN (MT-IPMN) who had diabetes was significantly higher than among those with branch-duct IPMN (BD-IPMN) (<i>p</i> &lt; 0.05). The average postoperative hospital stay for patients with low-grade dysplasia (LGD) was 17.7 days (range, 6–53 days), while for patients with HGD/IC, it was 25.5 days (range, 9–90 days), with a statistically significant difference (<i>p</i> &lt; 0.05). Jaundice, elevated CA19-9, elevated CEA, main duct (MD) &gt; 10 mm, and IPMN subtype were significant predictors of HGD/IC (<i>p</i> &lt; 0.05), with elevated CA19-9 and IPMN subtype identified as independent risk factors (<i>p</i> &lt; 0.05). The 2023 Kyoto guidelines showed higher sensitivity but lower specificity than the 2017 Fukuoka guidelines for detecting HGD/IC (<i>p</i> &lt; 0.05 for both). There was a statistically significant difference in overall survival between patients with LGD and those with HGD/IC following surgery (<i>p</i> &lt; 0.05), while no significant difference in postoperative survival was observed between HGD/IC patients with and without lymph node metastasis (<i>p</i> &gt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Surgical resection is recommended for elderly patients with MD-IPMN or MT-IPMN combined with elevated CA19-9. The 2017 Fukuoka guidelines are preferable to the 2023 Kyoto guidelines for managing elderly IPMN patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":32862,"journal":{"name":"Aging Medicine","volume":"8 3","pages":"221-228"},"PeriodicalIF":2.2,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/agm2.70022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144550921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Atherogenic Index of Plasma and Hypertension in Chinese Middle-Aged and Older Adults: A Cross-Sectional and Longitudinal Analysis Based on CHARLS","authors":"Xiao Chen,&nbsp;Lerui Wang,&nbsp;Weicheng Lai,&nbsp;Boda Zhou","doi":"10.1002/agm2.70015","DOIUrl":"https://doi.org/10.1002/agm2.70015","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Atherosclerosis is the underlying pathology of cardiovascular disease (CVD), including hypertension. Unfortunately, the association between the atherogenic index of plasma (AIP) and hypertension has not been reported in a large-scale middle-aged and elderly population. This study aimed to evaluate the association between AIP and hypertension in a representative middle-aged and elderly population in China.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The present study was a retrospective cohort study. We conducted cross-sectional and longitudinal analysis using data from the China Health and Retirement Longitudinal Study (CHARLS) from 2011 to 2018. Hypertension was identified by self-report or by taking antihypertensive medications. Participants aged below 45 years, with missing data on AIP, hypertension records, or taking lipid-lowering medication were excluded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 12,376 participants were included in the cross-sectional analysis; we found that after adjusting for covariates, each unit increment in AIP was associated with a 109.0% increased prevalence of hypertension (OR = 2.090, 95% CI: 1.776–2.459), a 41.2% increased likelihood of systolic blood pressure (SBP) above 140 mmHg (OR = 1.412, 95% CI: 1.199–1.664), and a 43.9% increased likelihood of diastolic blood pressure (DBP) above 90 mmHg (OR = 1.439, 95% CI: 1.153–1.795). A total of 5649 participants were included in the longitudinal analysis; we found that every one-unit increase in AIP was associated with a 57.7% increase in hypertension incidence (OR = 1.577, 95% CI: 1.282–1.941, <i>p</i> &lt; 0.001) during 7 years follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These results demonstrated a significant positive association between AIP and the prevalence and incidence of hypertension in a nationwide representative middle-aged and elderly population in China.</p>\u0000 </section>\u0000 </div>","PeriodicalId":32862,"journal":{"name":"Aging Medicine","volume":"8 2","pages":"107-116"},"PeriodicalIF":2.2,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/agm2.70015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143930517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-Period-Cohort Analysis and Prediction of Falls Disease Burden Attributable to Low Bone Mineral Density in China, 1990–2019","authors":"Ping Wang,&nbsp;Qingping Liu,&nbsp;Jing Wang,&nbsp;Jing Du,&nbsp;Chao Tong,&nbsp;Zaihua Wei,&nbsp;Jianting Su","doi":"10.1002/agm2.70019","DOIUrl":"https://doi.org/10.1002/agm2.70019","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aims to comprehensively describe and analyze the disease burden of falls attributed to low bone mineral density (BMD) in China from 1990 to 2019. Furthermore, we seek to predict the future trends of this burden from 2020 to 2030 to inform evidence-based prevention and control strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using data from the 2019 Global Burden of Disease (GBD) study, we conducted an in-depth analysis of mortality and disability-adjusted life year (DALY) trends related to falls attributed to low BMD in China from 1990 to 2019. An age-period-cohort (APC) model was employed to estimate mortality risk, accounting for age, period, and cohort effects. A Bayesian framework was utilized to project mortality and DALY rates for the period 2020–2030.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From 1990 to 2019, there was a significant increase in both crude death rate (224.79%) and DALY rate (196.27%) among the Chinese population affected by falls due to low bone mineral density. The standardized death rate was higher among males compared to females; however, the standardized DALY rate remained lower than that observed among females throughout this period. Importantly, China witnessed a greater surge in deaths and DALYs compared with global figures as well as other socio-demographic index regions during this time frame. The APC model demonstrated a global change of 1.06% (95% confidence interval [CI]: 0.910–1.210) for men and 0.29% (95% CI: 0.147–0.426) for women over time. The death rate increased across all age groups for men, while it specifically increased for women aged 62.5 years and older. The risk of mortality dramatically escalates for individuals over 80 years old. Projections indicate a decline in the standardized mortality rate from falls due to low bone mineral density in both men and women in China during the period of 2020–2030; however, an increase is anticipated in the standardized DALY rate.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The mortality risk associated with falls due to low BMD in China is influenced by age, period, and cohort effects. Strengthening fall prevention and treatment strategies for older adults and younger birth cohorts, as well as addressing fall-related disabilities, is crucial to reducing the substantial burden posed by non-fatal falls. Targeted interventions are needed to mitigate the growing health and economic impacts of this public health issue.</p>\u0000 </section>\u0000 </div>","PeriodicalId":32862,"journal":{"name":"Aging Medicine","volume":"8 2","pages":"91-98"},"PeriodicalIF":2.2,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/agm2.70019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143930475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors and Predictive Model for Ischemic Complications in Endovascular Treatment of Intracranial Aneurysms: Insights From a Large Patient Cohort","authors":"Jianwen Jia,&nbsp;Zeping Jin,&nbsp;Mirzat Turhon,&nbsp;Yixin Lin,&nbsp;Xinjian Yang,&nbsp;Yang Wang,&nbsp;Yunpeng Liu","doi":"10.1002/agm2.70021","DOIUrl":"https://doi.org/10.1002/agm2.70021","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>There remains a conspicuous absence of systematic analysis concerning the risk factors for the development of ischemic complications in the interventional treatment of IAs. Our study aimed to identify the risk factors for ischemic complications after the interventional treatment of IAs and to make an individualized prediction of the occurrence of ischemic complications, providing important reference guidance for clinicians.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study encompassed a sample of 473 patients diagnosed with intracranial aneurysms (IA) and treated at our center between February 2022 and April 2024. Ischemic complications were identified via clinical symptomatology and corroborated with diagnostic subtraction angiography (DSA), computed tomography (CT), or magnetic resonance imaging (MRI). We used a machine learning (ML) approach to screen potential variables for ischemic complications and identify correlations between them, and subsequently constructed a logistic regression model to quantify these correlations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients were categorized based on the occurrence or absence of ischemic complications. A total of five potential factors were screened using LASSO regression, XGBoost, and Randomforest algorithms: hypertension, history of alcohol consumption, multiple IAs, rupture status, and antiplatelet agent. Multivariate analysis further disclosed that hypertension, history of alcohol consumption, ruptured aneurysms, and antiplatelet agent were independent risk factors for postoperative ischemic complications. The predictive model, derived from the multivariate regression analysis results, demonstrated robust reliability.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Hypertension, history of alcohol consumption, ruptured aneurysms, and antiplatelet agent as independent risk factors for ischemic complications following the interventional treatment of IAs. Accordingly, we constructed the first risk prediction model regarding ischemic complications of all IAs based on these factors, aiming to enhance prognostic judgment and treatment strategy planning.</p>\u0000 </section>\u0000 </div>","PeriodicalId":32862,"journal":{"name":"Aging Medicine","volume":"8 2","pages":"126-136"},"PeriodicalIF":2.2,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/agm2.70021","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143930474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}